Introduction
Melanoma differentiation-associated gene-7 (mda-7), also classified as interleukin-24 (IL-24), was initially identified by subtraction hybridization in human melanoma cells induced to terminally differentiate by treatment with recombinant fibroblast interferon and mezerein (Jiang et al., 1995) . Multiple independent studies document that mda-7/IL-24 induces growth arrest and apoptosis in human cancer cell lines of diverse origin in vitro and inhibits human tumor xenograft growth in vivo in nude mice (reviewed by Fisher et al., 2003; Chada et al., 2004b; Fisher, 2005; Lebedeva et al., 2005a; Gupta et al., 2006; Sarkar et al., 2006) . These studies also confirm that ectopic overexpression of mda-7/IL-24 does not affect growth or viability in normal cells. Additionally, mda-7/IL-24 overexpression inhibits tumor angiogenesis and invasion Su et al., 2005) , and enhances tumor sensitivity to radiation Yacoub et al., 2003a Yacoub et al., , b, 2004 Lebedeva et al., 2005b; Su et al., 2006) , chemotherapy (Chada et al., 2005b; Oida et al., 2005) and monoclonal antibody therapy (Chada et al., 2005b) . The mechanisms underlying these diverse effects are currently under intense scrutiny (Fisher, 2005) .
Colorectal cancer is the third most common malignancy in Western nations, displaying a poor prognosis without a significant improvement in survival rates over the past 40 years (Viale et al., 2005) . Initiation and progression of colorectal cancer is a multistep process and involves accumulation of multiple genetic abnormalities that develop in a defined temporal manner (Vogelstein et al., 1988; Fearon and Vogelstein, 1990) . K-ras is frequently mutated (B40-50%) in colorectal cancers (Bos et al., 1987; Vogelstein et al., 1988) . Moreover, acquisition of this mutation significantly increases the risk of recurrence and reduces overall survival (Andreyev et al., 2001) , partly because cells harboring ras oncogenes become more resistant to radiotherapy and chemotherapy (Sklar, 1988a, b) . G-T and G-C transversions of the K-ras gene in codon 12 may lead to biological effects in vitro and in vivo, which are associated with an abnormal cell cycle and increased tumor aggressiveness. In these contexts, mutated ras oncoproteins are thought to alter cellular signaltransduction pathways (Barbacid, 1987) and to affect neoplastic growth of colorectal cancer. In vitro data indicate that the oncogenic effects of activated ras genes may be mediated, at least in part, through inhibition of apoptotic cell death, thus favoring tumor progression (Ward et al., 1997) . These findings suggest that targeting K-ras expression, either directly or its downstream signaling pathways, may improve the efficacy of treatment of colorectal cancer. Various approaches have been used to achieve this objective of inhibiting ras protein levels in cells, including ribozymes, antisense (AS) oligonucleotides and cDNA, farnesyl-transferase inhibitors, dominant-negative mutants and intracellular antibodies (reviewed by Adjei, 2001; Canevari et al., 2002) .
In the present study, we tested the hypothesis that blocking K-ras expression in mutant K-ras colorectal cancer cells would increase their sensitivity to Ad.mda-7. This possibility was evaluated using three approaches to downregulate K-ras expression. An adenovirus was used to deliver an intracellular antibody expressing a single-chain F V (scF V ) fragment directed to K-ras, Ad.K-ras single-chain antibody (scAb) (Russell et al., 1999) . Additionally, adenoviruses expressing K-ras AS or simultaneously expressing both mda-7/IL-24 and K-ras AS (Ad.m7.KAS) were used to downregulate p21 RAS protein. When mda-7/IL-24 expression was accompanied by K-ras downregulation, growth suppression and apoptosis were enhanced in mutant K-ras colorectal carcinoma cells. These results suggest that strategies designed to block ras expression in combination with mda-7/IL-24 expression may provide an innovative means of enhancing the clinical efficacy of mda-7/ IL-24 in the context of colorectal cancer.
Results
Colorectal carcinoma cells are sensitive to a low multiplicity of adenoviral infection with Ad.K-ras scAb, but not with Ad.mda-7 or Ad.K-ras AS Five colorectal carcinoma cell lines that differ in K-ras and p53 phenotypes were used in the present study: HCT-15 (mut K-ras, heterozygous p53), HCT 116 (mut K-ras, wild-type (wt) p53), SW620 (mut K-ras, mut p53), HT29 (wt K-ras, mut p53) and RKO (wt K-ras, wt p53) (Russo et al., 2002) . Preliminary experiments demonstrated that these colorectal cancer cells were sensitive to adenoviral infection, and even small differences in virus titer profoundly affected cell viability. In general, a high concentration (100 plaqueforming units (pfu)/cell) of all of the viruses (including Ad.vec) decreased viability of these colorectal carcinoma cell lines; however, these effects appear to be virus-and not gene-specific (Figure 1a ). With lower multiplicity of infections (m.o.i.'s) (25 pfu/cell for HCT-15 and HCT 116, 50 pfu/cell for SW620 and RKO cells and 100 pfu/ cell for HT29 cells), no significant decreases in viability were observed with Ad.vec and little effect was observed with Ad.mda-7 (Figure 1b) . Treatment of HCT-15 and HCT 116 cells with 20 pfu/cell of Ad.vec or SW620 or RKO cells with 50 pfu/cell of Ad.vec resulted in B80-85% viable cells. The same treatment with Ad.mda-7 resulted in B70-80% viable cells in these three cell lines. HT29 (wt K-ras) cell viability was unaffected after infection with up to 100 pfu/cell of Ad.vec or Ad.mda-7. Comparable viability decreases (B30-25%) were evident with higher doses of these viruses. In contrast, infection with similar m.o.i.'s of Ad.K-ras scAb decreased viability in colorectal cells containing a mutated K-ras gene, although this effect was not profound. Based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays (day 6), viability of HCT-15 and HCT 116 cells (25 pfu/cell) and SW620 cells (50 pfu/cell) diminished to B60% (Figure 1b) . In cells manifesting wt K-ras (HT29 and RKO), the viability decrease promoted by Ad.K-ras scAb treatment (50 pfu/cell) was B20% and not significantly different from infection with a similar m.o.i. of Ad.vec. Infection of any of the colorectal cancer cell lines with Ad.K-ras AS at doses up to 50 pfu/cell did not promote significant growth inhibitory effects.
Fluorescent-activated cell sorting (FACS) analysis was used to quantify Coxsackie and adenovirus receptor (CAR) levels in the different colorectal carcinoma cultures following staining with anti-CAR antibodies. All cell lines used in the present study, except RKO cells, possess approximately similar high levels of CAR that are needed for adenoviral entry (Figure 1a ). Additional infectivity studies with an Ad.GFP virus and subsequent FACS assays determined that m.o.i.'s of 25 pfu/cell for HCT-15 and HCT 116, 50 pfu/cell for HT29 cells and 75 pfu/cell for SW620 cells were sufficient to transduce green fluorescence protein in B80% of the virally infected cells (Figure 1a ). Based on their lower concentration of CAR, RKO cells required 100 pfu/cell of Ad.GFP to transduce B75% of the cells. Previous studies indicate that infection at a high multiplicity (more than required for 100% gene transfer) with a replication-deficient adenovirus induces apoptosis and G 2 /M arrest in specific cell lines (Brand et al., 1999) . To avoid this problem and based on toxicity of higher doses of virus in specific colorectal cancer cell lines, we used predefined doses of viruses for further studies, 25 pfu/ cell for HCT-15 and HCT 116, 50 pfu/cell for HT29 cells, 75 pfu/cell for SW620 cells and 100 pfu/cell for RKO cells.
A combination of Ad.mda-7 plus Ad.K-ras AS or Ad.K-ras scAb increases antisurvival effects in mut K-ras colorectal carcinoma cells MTT assays were used to determine the effect of Ad.Kras scAb, Ad.K-ras AS and Ad.mda-7, used alone and in combination, and the effect of Ad.m7.KAS bipartite virus on cell survival. HCT-15 and HCT 116 cells were infected with a combination of viruses not exceeding 25 pfu/cell, and SW620 and HT29 cells were infected with a combination of viruses not exceeding 75 pfu/cell. RKO cells were infected with 100 pfu/cell of total virus. Whereas infection with a single agent at a low m.o.i., 12.5 or 25 pfu/cell depending on the cell type, did not induce significant decreases in viability, the combination of Ad.mda-7 with Ad.K-ras scAb or Ad.K-ras AS efficiently reduced viability in colorectal carcinoma cell lines with mutated K-ras. In general, Ad.K-ras AS was more efficient than Ad.K-ras scAb in combination with Ad.mda-7 in promoting decreased viability in colorectal cancer cells with mut K-ras (Figure 1b) . In contrast, neither single nor combination of viral infection at 25 or 50 pfu/cell significantly altered viability of HT29 or RKO cells, which contain wt K-ras (Figure 1b) . The novel bipartite virus Ad.m7.KAS induced efficient viability decreases in mut K-ras cells (Figure 1b) . The efficiency of inducing decreased viability by 100 pfu/cell of the bipartite virus was generally greater than combinations of Ad.mda-7 and either of the K-ras nullifying viruses (total of 100 pfu/cell). However, this virus was also inefficient in affecting viability in the wt K-ras cell lines, HT29 and RKO.
Temporal and dose-dependent expression of mda-7/IL-24 mRNA and protein upon Ad.mda-7 infection Mda-7/IL-24 mRNA expression after Ad.mda-7 infection of colorectal carcinoma cells was determined by Northern blotting. Infection with Ad.mda-7 resulted in a time-and dose-dependent expression of mda-7/IL-24 mRNA, which was evident as early as 6 h post-infection with doses as low as 1 pfu/cell (Figure 2a ). MDA-7/ IL-24 protein was detected using Western blotting assays in HCT-15 and HCT 116 cells after low-dose (25 pfu/cell) infection with Ad.mda-7 virus, and its expression increased with the m.o.i. of virus used ( Figure 2b ). In SW620 and RKO cells, MDA-7/IL-24 protein was detected after infection with 50 pfu/cell of Ad.mda-7. In contrast, a combination of a low dose of Ad.mda-7 (10 pfu/cell for HCT-15 and HCT 116 cells, and 25 pfu/cell for SW620) with Ad.K-ras AS or Ad.Kras scAb viruses (total m.o.i. of 20 pfu/cell for HCT-15 and HCT 116 and 50 pfu/cell for SW620 cells) or single infection with Ad.m7.KAS virus increased MDA-7/ IL-24 protein expression significantly compared to levels detected following a single infection with Ad.mda-7 ( Figure 3a ). Of note, the combination of Ad.mda-7/ IL-24 with Ad.K-ras AS or exclusively Ad.m7.KAS virus infection produced more MDA-7/IL-24 protein than the combination of Ad.mda-7 with Ad.K-ras scAb ( Figure 3a) . Expression of MDA-7/IL-24 protein was not detected in HT29 cells following infection with 100 pfu/cell of Ad.mda-7 virus, Ad.m7.KAS or after combination (Ad.mda-7 plus Ad.K-ras AS) treatment (50 pfu/cell of each virus), whereas low-level expression of MDA-7/IL-24 protein was detected following infection with 200 pfu/cell of Ad.mda-7 (Figures 2b and 3a) . In the case of RKO cells, low level of MDA-7/IL-24 protein was detected after combination treatment with Ad.mda-7/IL-24 plus Ad.K-ras AS or following infection with the bipartite virus Ad.m7.KAS ( Figure 3a ).
Infection of colorectal cancer cells with Ad.K-ras AS, Ad.K-ras scAb or Ad.m7.KAS decreases p21 K-RAS protein levels and downstream signaling pathways Colorectal cancer cells infected with Ad.K-ras AS or Ad.K-ras scAb, alone and in combination with Ad.mda-7, or with Ad.m7.KAS were analysed to determine p21 K-RAS protein levels by Western blotting. Ad.K-ras scAb used alone or in combination with Ad.mda-7 significantly downregulated K-RAS protein expression in all five colorectal carcinoma cell lines (Figure 3a) . However, using Ad.K-ras AS alone and in combination with Ad.mda-7, we were able to achieve enhanced downregulation of p21 K-RAS in HCT-15, HCT 116 and SW620 cells. In HT29 and RKO cells, both viruses displayed the same efficiency of suppression of K-RAS protein. Ad.m7.KAS virus completely extinguished K-RAS protein expression in HCT 116 and HT29 colorectal cancer cell lines 24 h post-infection ( Figure 3a) . In HCT-15, SW620 and RKO cell lines, the bipartite virus achieved approximately the same degree of downregulation of p21 K-RAS as Ad.K-ras AS alone or plus Ad.mda-7.
To confirm the functionality of these viruses in blocking p21 K-ras activity, we determined the state of activation of p42 MAPK using antibodies recognizing phosphorylated forms of this kinase and total MAPK. In concurrence with the previous data, phosphorylation of MAPK was inhibited in all samples infected with K-ras nullifying viruses ( Figure 3b ). The inhibition of phosphorylation was more pronounced following infection with Ad.K-ras AS or Ad.m7.KAS than with Ad.K-ras scAb. Targeted downregulation of K-ras expression combined with mda-7/IL-24 promotes apoptosis in mut K-ras colorectal cancer cells without altering cell cycle Colorectal carcinoma cells were infected with different viruses, alone and in combination, as described above, and analysed for the induction of apoptosis by Annexin V binding assays and by propidium iodide (PI) staining with subsequent FACS assays. Cell cycle changes were also monitored by FACS assays using cells fixed with 70% ethanol and stained with PI. Both apoptosis assays provided comparable results. All viruses, when employed alone at the doses indicated previously, demonstrated some (although not very high) levels of apoptosis compared to Ad.vec-infected cells, especially HCT-15 cells that are most sensitive to viral infection (Figure 1a ). Based on Annexin V staining, apoptosis induction following Ad.mda-7 infection varied between 5% in SW620, HT29 and RKO cells and 15% in HCT 116 cells. Both Ad.K-ras AS and Ad.K-ras scAb induced 5-7% apoptosis in SW620, HT29 and RKO cells, B10% in HCT 116 cells and B20% apoptosis in HCT-15 cells. Apoptosis induction was shown to be viral dose-dependent, which correlated with the killing effect (Figure1a and data not shown). When Ad.mda-7 was combined with Ad.K-ras scAb virus, the percentage of apoptotic cells increased in colorectal carcinomas with mut K-ras (>20% in SW620 and HCT-15 cells and B40% in HCT 116 cells), but not in wt K-ras HT29 or RKO cells (Figure 4) . However, the increase was additive rather than synergistic (especially in the case of HCT-15 cells that were most sensitive to adenoviral infection), whereas in SW620 cells, the effect of combinational treatment appeared greater than additive. A combination of Ad.mda-7 plus Ad.K-ras AS or Figure 3 Effect of infection with Ad.mda-7, Ad.K-ras scAb and Ad.K-ras AS, alone and in combination, and Ad.m7.KAS on MDA-7/IL-24 and K-RAS protein expression and ERK1/2 phosphorylation in colorectal carcinoma cells. (a) Effect of viral infection on MDA-7/IL-24, p21 K-RAS and EF-1a protein levels in various colorectal carcinoma cells. The indicated cell types were infected with different m.o.i.'s of the indicated viruses as described in the Results section and protein levels were determined 24 h after infection by Western blotting. (b) Effect of infection with various adenoviruses alone or in combination on ERK1/2 phosphorylation. The indicated cell types were infected with Ad.vec, Ad.mda-7 alone or in combination on Ad.K-ras scAb or Ad.K-ras AS and with Ad.m7.KAS, and levels of total and phosphorylated ERK1/2 were determined after 24 h by Western blotting as described in Materials and methods.
single infection with Ad.m7.KAS induced a somewhat higher degree of apoptosis in all three mut K-ras cell lines. Measurements of cells in the sub-G 0 population (A 0 ), containing a hypodiploid DNA content (another indicator of apoptosis), corroborated the data obtained with Annexin V staining (Figure 4b ). In contrast, treatment of colorectal carcinoma cells with Ad.mda-7 alone and in combination with Ad.K-ras AS or Ad. K-ras scAb virus as well as with the Ad.m7.KAS virus did not cause any changes in cell cycle (PI staining and FACS assay) (data not shown).
Combination of mda-7/IL-24 and inhibition of K-ras expression changes the ratio between pro-and antiapoptotic BCL-family protein members in mut K-ras colorectal cancer cells Previous studies in a number of different tumor types indicated that infection with Ad.mda-7 resulted in a change in the ratio of proapoptotic (including BAX and BAK) to antiapoptotic proteins (including BCL-2 and BCL-x L ), thereby facilitating a shift from cell survival to death (Su et al., 1998 (Su et al., , 2001 Lebedeva et al., 2002 Lebedeva et al., , 2003 . In this context, the effect of infection with the different viruses, alone or in combination, on BCLfamily protein levels was determined 48 h post-infection by Western blotting ( Figure 5 ) and changes were normalized to EF-1a expression and compared with Ad.vec infection (Table 1) . BCL-2 and BCL-x L protein levels were variably downregulated after infection of all three mut K-ras colorectal cancer cell lines with Ad.Kras AS or Ad.K-ras scAb in combination with Ad.mda-7 or infection with Ad.m7.KAS. Similar infection protocols also variably enhanced expression of BAX and/or BAK in the three mutant K-ras colorectal cancer cell types (Table 1 ). In sensitive cell lines, both BCL-2 and BCL-x L proteins were downregulated to variably extents by combination treatment, whereas BAK (except in HCT 116 cell line) and especially BAX were upregulated (Table 1 and Figure 5 ). In contrast, in HT29 cells, containing a wt K-ras gene, only small changes were observed in BCL-family members and the changes in proapoptotic proteins were counterbalanced by changes in the antiapoptotic proteins. In the case of RKO cells, which also have a wt K-ras genotype, the relative balance between anti-and proapoptotic factors also maintained a ratio that did not promote cell death (Figures 1b and 4a) . In specific cellular contexts, increased levels of BCL-x L expression may compensate decreased levels of BCL-2 expression. BAX expression did not change significantly (except for a slight increase after Ad.m7.KAS treatment), and the levels of BAK expression were intensely altered (Table 1 and Figure 5 ). These results provide further documentation of the importance of changes in the ratio of multiple BCLfamily members, that is, upregulation of proapoptotic and downregulation of antiapoptotic proteins, in rendering cancer cells susceptible to apoptosis induction by mda-7/IL-24. In the case of colorectal cancer cells, blocking K-ras expression in mutant K-ras colorectal cancers facilitates the ability of mda-7/IL-24 to alter the levels of these proteins, whereas blocking K-ras in wt K-ras colorectal cancer cells does not elicit a similar response to mda-7/IL-24.
Discussion
Colorectal cancer has a poor prognosis and improvement in survival rates over the past 40 years has been disappointing. Surgical resection is highly effective for early-stage colon cancers. In advanced stages, when surgery is not feasible, chemotherapy provides only palliative benefit with a modest increase in survival and quality of life, but the majority of patients succumb to metastatic disease within 2 years. In this context, a dire need exists to develop improved therapies. Gene therapy provides a viable option, especially when employed with a cancer-selective apoptosis-inducing gene such as mda-7/IL-24, which induces a direct antitumor effect and profound antitumor 'bystander' activity (Su et al., 2001 Fisher et Lebedeva et al., 2005a) . Although mda-7/IL-24 functions as an efficient antitumor and apoptosis-inducing gene in diverse cancer cells in vitro and in vivo, our initial studies demonstrated its low killing efficiency in pancreatic and specific colorectal carcinoma cells in vitro (Su et al., 2001; Lebedeva et al., 2005b; Lebedeva et al., 2006 ; IV Lebedeva, Z-Z Su and PB Fisher, unpublished data). A possible explanation for this phenomenon could be the frequent mutations of K-ras observed in pancreatic (Bos, 1989) and colorectal carcinomas (Bos et al., 1987) that might impact on the ability of mda-7/IL-24 to induce apoptosis in these two cancer cell types (Su et al., 2001; Lebedeva et al., 2005b; Lebedeva et al., 2006) . Several studies suggest that downregulation of K-ras expression may be of benefit in the treatment of pancreatic (Aoki et al., 1997; Kita et al., 1999) and colorectal (Mukhopadhyay et al., 1991; Shirasawa et al., 1993; Cochet et al., 1998) cancers. These findings imply that this oncogene may provide a viable target for inactivation, thereby improving response to other therapies. This indeed appears to be the case as exemplified by the present study in which targeting K-ras for extinction promotes the ability of mda-7/IL-24 to kill mut K-ras colorectal cancer cells.
Ras genes encode GTP-binding proteins with hydrolytic activity that allows them to control cell proliferation by regulating defined signal-transduction pathways (Bos, 1989) . In their constitutively active, deregulated GTP-bound form (e.g., by point mutation), p21 Ras stimulates a signaling cascade promoting cancer cell growth (Barbacid, 1987) . Evidence of increased signaling through the Ras-ERK pathway is suggested by the observation that activated phosphorylated ERK1/2 is expressed in a high proportion of tumor cell lines and primary tumor-derived cell cultures from the colon (Hoshino et al., 1999) . In the present study, we employed two approaches to inhibit K-ras expression and downstream signaling, a single-chain neutralizing Figure 5 Effect of infection of colorectal carcinoma cells with Ad.vec, Ad.mda-7, Ad.K-ras scAb and Ad.K-ras AS, alone and in combination with Ad.mda-7, or Ad.m7.KAS viruses on BCL-family protein expression. Cells were treated as indicated, protein lysates were collected after 48 h, and analysed by Western blotting for BCL-2, BCL-x L , BAX and BAK expression as described in Materials and methods. To confirm equal loading, each blot was reprobed with an EF-1a antibody. anti-K-ras antibody and an AS K-ras gene construct. Previous studies document that intracellular expression of a scF V fragment of a neutralizing anti-RAS monoclonal antibody specifically inhibits the ras signaling pathway in Xenopus laevis oocytes and NIH 3T3 fibroblasts (Cochet et al., 1998) . Moreover, neutralizing RAS with the scF V specifically promoted apoptosis in vitro in human cancer cells, but not in non-transformed cells (Cochet et al., 1998) . The scAb fragment is highly aggregated when cytoplasmically expressed and p21-RAS antigen is sequestered in these aggregates in an antibody-dependent manner (Cardinale et al., 1998 ). We presently demonstrate that infection with an Ad encoding a scAb against K-ras efficiently eliminates RAS protein from the cytoplasm, presumably by binding to and consequently blocking activity of this oncogenic protein. Western blot assays confirmed downregulation of p21 K-RAS protein, likely resulting from aggregation with the antibody. Inactivation of the K-ras signaling pathway was further confirmed by the assay of one of the downstream targets of K-ras, namely p42 MAPK (Figure 3b ). Ad.K-ras scAb deactivated K-ras, which is confirmed by downregulation of phosphorylated ERK in all cell lines evaluated in the present study, both with mut and wt K-ras. Inactivation of K-ras was also achieved using an AS K-ras gene targeting strategy . We employed two viruses, one expressing an AS K-ras gene construct targeting the K-ras initiation codon (Ad.K-ras AS) and another that simultaneously expresses both an mda-7/IL-24 gene and the same AS K-ras construct (Ad.m7.KAS). As seen in Figure 3 , both viruses potently downregulated p21 K-RAS protein levels in colorectal carcinoma cells irrespective of their K-ras status. Both of the viruses also inhibited downstream K-ras-ERK signaling, as confirmed by inhibition of p42 MAPK phosphorylation (Figure 3b ). The level of AS-mediated downregulation of K-ras expression and downstream signaling was greater than the downregulation provided by the scAb virus (Figure 3) . A possible explanation of this phenomenon could be that AS inhibition occurs at the level of mRNA, whereas in the case of the singlechain neutralizing antibody, inhibition occurs at the level of protein without altering mRNA expression. In this situation, as a result of incomplete translation inhibition by the single-chain neutralizing antibody, it is less efficient versus targeted inhibition at an mRNA level using the AS strategy.
Downregulation of K-ras activity in colorectal cancer cells containing mut K-ras sensitized these cells to Ad.mda-7-induced killing (Figure 1b ). When treated with Ad.mda-7 alone at low m.o.i.'s, devoid of a nonspecific killing effect, colorectal cancer cells did not express high levels of MDA-7/IL-24 protein. Downregulation of mutated K-ras allowed MDA-7/IL-24 protein to be expressed efficiently, leading to growth suppression and apoptosis. Moreover, the degree of killing directly correlated with the level of MDA-7/IL-24 protein expressed by a particular colorectal cancer cell line (Figures 3a and 4) . These findings argue that there is a threshold level of MDA-7/IL-24 that must be achieved to induce apoptosis and this level may vary in different cancer cells. Ad.K-ras AS provided enhanced K-ras downregulation and inhibition of its downstream signaling compared with Ad.K-ras scAb (Figure 3 ). This improved downregulation of K-ras correlated with increased MDA-7/IL-24 protein and an enhanced ability of these viruses in combination with Ad.mda-7 to kill mutant K-ras colorectal carcinomas. Improved antitumor activity was apparent using the bipartite virus, Ad.m7.KAS, which likely relates to the improved delivery of threshold levels of both gene products to target cells.
The mechanism by which blocking K-ras signaling facilitates mda-7/IL-24-induced killing of mut K-ras colorectal cancer cells is not currently known. In the case of pancreatic cancers with mutated K-ras genes, which are resistant to Ad.mda-7 induction of cell death, this mutated oncogene is responsible for a block in MDA-7/IL-24 translation (Su et al., 2001; Lebedeva et al., 2005b Lebedeva et al., , 2006 . In the case of pancreatic carcinoma cells infected with Ad.mda-7, mRNA is efficiently expressed (Su et al., 2001; Lebedeva et al., 2005b) , but this mRNA is found mainly in a free state, unassociated with polysomes . In contrast, when K-ras or its downstream signaling pathways are inhibited, there is a shift from non-polysome-associated to polysome-associated mda-7/IL-24 mRNA, thereby resulting in the production of MDA-7/IL-24 protein and induction of apoptosis uniquely in mutant K-ras pancreatic cancer cells . Further studies are necessary to determine if a similar 'translational block' in conversion of mda-7/IL-24 mRNA into protein is also operational in specific K-ras mutated colorectal cancer cells and inhibiting K-ras expression relieves this block. Another possible reason for the lack of MDA-7/IL-24 protein expression in specific colorectal carcinoma cells after single low-dose Ad.mda-7 infection could be a rapid degradation of newly synthesized protein. In this context, inhibition of K-ras expression may change the kinetics of degradation and synthesis of MDA-7/IL-24 protein. Additional studies are required to elucidate the mechanism underlying the enhanced activity of Ad.mda-7 infection and inhibition of K-ras signaling in mediating enhanced killing of mutant K-ras colorectal cancer cells.
It is hypothesized that cancer cells may be dependent on the continued expression of a single mutated or overexpressed oncogene (Weinstein, 2002) . In this context, these tumors are 'addicted' to this oncogene, requiring its continued expression for survival. The fact that simultaneous K-ras inhibition and mda-7/IL-24 expression is very efficient in killing colorectal carcinoma cells with mut K-ras, while not killing wt K-ras colorectal carcinomas, even though K-ras and downstream ERK kinases are equally downregulated in both cell types, suggest that mutant K-ras (but not wt K-ras) colorectal carcinoma cells are 'addicted' to the K-rasmediated signaling pathway.
The protooncogene bcl-2 is overexpressed in many human cancers, including breast (Krajewski et al., 1997) , prostate (Krajewska et al., 1996a) , and colorectal carcinomas (Hague et al., 1994; Krajewska et al., 1996b) . Colorectal tumors with mutant K-ras have a significantly lower apoptotic index than those with a wt allele. They are also more likely to exhibit bcl-2 positive staining (Ward et al., 1997) . The finding that activated K-ras is associated with increased bcl-2 expression raises the possibility that this may represent the mechanism whereby K-ras suppresses apoptosis in colorectal neoplasia. The physiological control of bcl-2 is complex, and the function of the oncoprotein is influenced by dimerization with other proteins of the bcl-2 family, as well as other proteins including RAF-1 and R-RAS (Fernandez-Sarabia and Bischoff, 1993) . Expression of bcl-2 can be influenced by the activation of the ras signaling pathway (Kinoshita et al., 1995) . Using a murine IL-3-dependent myeloid cell line, Kinoshita et al. (1995) demonstrated that expression of bcl-2, both at the message and protein levels, was upregulated after transfection with activated c-H-ras, and this was responsible for the subsequent inhibition of apoptosis. We now demonstrate that downregulation of mutated K-ras in combination with Ad.mda-7 infection leads to downregulation of antiapoptotic and upregulation of proapoptotic BCL-protein family members corresponding with an increase in apoptosis ( Figure 5 and Table 1 ). Previous studies document that Ad.mda-7 infection of diverse cancer cells in vitro results in an altered ratio of BCL-family protein levels, increasing the levels of the proapoptotic proteins (Su et al., 1998 (Su et al., , 2001 Lebedeva et al., 2002 Lebedeva et al., , 2003 . In colorectal carcinoma cells, Ad.mda-7 infection alone at the low doses employed did not change the levels of BCL-family proteins ( Figure 5 and data not shown). However, inactivation of mutated K-ras led to increased sensitivity to mda-7/IL-24-induced killing and apoptosis and changes in the levels of the BCL-family members.
In summary, we presently document that inhibition of K-ras signaling in mutant K-ras colorectal cancer cells renders these cells more sensitive to apoptosis induction by mda-7/IL-24. This ability to augment cell killing by the combinatorial approach involves enhanced expression of MDA-7/IL-24 protein and concomitant alterations in the levels of BCL-family proteins in tumor cells. Achieving a threshold level of MDA-7/IL-24 protein appears critical for the induction of apoptosis by this novel cytokine, as recently emphasized using a conditionally replication-competent adenovirus to deliver MDA-7/IL-24 to human colorectal cancer xenografts in nude mice, which resulted in significant activity in curing animals of tumors and prolonging their survival (Zhao et al., 2005) . The levels of expression of mda-7/IL-24 mRNA and protein resulting from delivery by the replicating virus greatly exceeded that of the non-replicating adenovirus in colorectal cancer cells, which demonstrated a less dramatic antitumor effect (Zhao et al., 2005) . In these contexts, approaches that augment the achievable level of MDA-7/IL-24 protein in cancer cells may prove beneficial in enhancing the antitumor activity of mda-7/IL-24.
Materials and methods

Cell culture and reagents
Human HCT-15, HCT 116, SW620 and HT29 colorectal carcinoma cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured in Roswell Park Memorial Institute medium 1640 (Life Technologies Inc., Grand Island, NY, USA), supplemented with 10% FBS and 1% penicillin and streptomycin (Life Technologies Inc.) at 371C in a 5% CO 2 95% air humidified incubator. Human RKO colorectal carcinoma cell line was kindly provided by Dr Jeffrey Schlom from the National Center Institute (NIH, Bethesda, MD, USA) and cultured in the same conditions as the other colorectal carcinoma cells.
Recombinant adenovirus constructs
The recombinant replication-incompetent Ad.mda-7 was created in two steps as described previously and plaque purified by standard procedures (Su et al., 1997 (Su et al., , 1998 Holmes et al., 2003) . The recombinant replication-deficient adenovirus vector Ad.K-ras scAb encodes the hypervariable regions of an anti-p21-RAS scAb driven by the human cytomegalovirus promoter was generated as described previously (Russell et al., 1999) and kindly provided by Dr S Chada (Introgen Therapeutics Inc., Houston, TX, USA). Ad.K-ras AS virus was produced by recombination as described and constructed by the Massey Cancer Center Virus Vector Shared Resource (Holmes et al., 2003) . The recombinant replication-defective Ad.m7.KAS bipartite virus was constructed using AdenoQuick Cloning System (OD 260 Inc., Boise, ID, USA) as previously described for the construction of Ad.PEG-E1A-IFN-g and Ad.PEG-E1A-mda-7 (Sarkar et al., 2005a, b) .
MTT viability assays
Viability assays were performed as described previously (Lebedeva et al., 2002) . Briefly, cells were seeded in 96-well tissue culture plates (1.5 Â 10 3 cells per well) and infected the next day with different adenoviruses. At the indicated time points, the medium was removed, and fresh medium containing 0.5 mg/ml MTT was added to each well. The cells were incubated at 371C for 4 h and then an equal volume of solubilization solution (0.01 N HCl in 10% SDS) was added to each well and mixed thoroughly. The absorbance from the plates was read on a Bio-Rad Microplate Reader Model 550 at 595 nm. A statistical analysis of the results was performed using the Analysis ToolPack provided by Microsoft Excel. A Student's two-sample t-test, assuming unequal variances, was used to determine the equality of the means of two samples. The confidence level (a) was 0.05.
Detection of CAR receptors on the cell surface Cells were harvested by trypsinization, washed 2 Â with phosphate-buffered saline (PBS) and stained with 1:1000 dilution of monoclonal anti-CAR antibody, for 1 h at 371C. After additional washings with PBS (2 Â 5 min), cells were stained in the dark for 1 h at 371C with a 1:500 dilution of fluorescein-labeled goat anti-mouse immunoglobulins (BioSource International, Camarillo, CA, USA). After washing with PBS, cells were analysed by flow cytometry (5 Â 10 5 cells per sample). Unstained cells and cells stained with monoclonal anti-SV40 antibody (Santa Cruz, Santa Cruz, CA, USA) and with secondary antibody only were used as controls. Two methods were used for semiquantitation of the results. The shift of FL1 peak was calculated as difference in peak channels between the control (cells unstained or stained with nonspecific antibody) and the experimental cells stained with anti-CAR antibody relative to the position of the control cell peak channel. The second method uses the Kolmogorov-Smirnov (K-S) test for overlaid histograms (Young, 1977) . The calculation computes the summation of the overlaid curves and determines the greatest difference between the summation curves (K-S statistics). D-value indicates the greatest difference between the two curves.
Apoptosis and necrosis assay (Annexin-V-binding assay) Cells were trypsinized and washed once with complete media. Aliquots of cells (5 Â 10 5 ) were resuspended in complete media (0.5 ml) and stained with fluorescein isothiocyanate-labeled Annexin-V (kit from Oncogene Research Products, Boston, MA, USA) according to the manufacturer's instructions. PI was added to the samples after staining with Annexin-V to exclude late apoptotic and necrotic cells. Flow cytometry was performed immediately after staining.
Cell cycle and hypodiploidy analyses Cells were trypsinized, washed 2 Â with PBS and fixed in 70% ethanol overnight at À201C. Cells were then washed 2 Â with PBS, and aliquots of 1 Â 10 6 cells were resuspended in 1 ml of PBS containing 1 mg/ml of RNase A and 0.5 mg/ml of PI. After 30 min of incubation, cells were analysed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
RNA isolation and Northern blotting analysis
Total RNA was extracted from cells using the Qiagen RNeasy minikit according to the manufacturer's protocol and was used for Northern blotting as described previously (Su et al., 1997) . Briefly, 15 mg of RNA for each sample was denatured, electrophoresed in 1.2% agarose gels with 3% formaldehyde and transferred onto nylon membranes. The blots were probed with an [a-32 P]dCTP, full-length human mda-7 cDNA probe, then stripped and reprobed with an [a-32 P]dCTP human glyceraldehyde-3-phosphate dehydrogenase probe. Following hybridization, the filters were washed and exposed for autoradiography.
Preparation of cell extracts and Western blotting analysis
Protein lysates were prepared on ice in radioimmunoprecipitation assay buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 1% NP40 and 0.5% sodium deoxycholate) with freshly added 0.1 mg/ml phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate and 1 mg/ml aprotinin. Protein concentrations were determined using the Bio-Rad protein assay system (Bio-Rad Laboratories, Richmond, CA, USA). Aliquots of cell extracts containing 20-50 mg of total protein were resolved in 12% SDS-polyacrylamide gel and transferred to 0.45 mm nitrocellulose membranes (Osmonics, Westborough, MA, USA). Filters were blotted using anti-EF-1a monoclonal (Upstate Cell Signaling, Lake Placid, NY, USA) and rabbit anti-MDA-7/IL-24, anti-BCL-2, anti-BCL-x L , anti-BAX, and anti-BAK polyclonal antibodies. Enhanced chemiluminescence was performed according to the manufacturer's recommendation. To determine ERK phosphorylation, blots were sequentially stained with anti-phospho-ERK mouse monoclonal and then with anti-ERK rabbit polyclonal antibodies (both antibodies were obtained from Santa-Cruz Biotechnology, Santa Cruz, CA, USA). BCL-family protein expression as determined by Western blot analysis was quantitatively analysed via laser-scanning densitometry using the NIH ImageJ Version 1.61 software. All results were normalized to EF-1a protein expression.
Statistical analysis
All the experiments were performed at least three times. The results are expressed as mean7s.e. Statistical comparisons were made using an unpaired two-tailed Student's t-test. A P-value o0.05 was considered to be significant.
Abbreviations
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